AKBA
Price
$1.84
Change
-$0.00 (-0.00%)
Updated
Nov 5, 04:50 PM (EDT)
2 days until earnings call
ALLK
Price
$1.35
Change
+$0.10 (+8.00%)
Updated
Nov 5, 04:50 PM (EDT)
6 days until earnings call
Ad is loading...

AKBA vs ALLK

Header iconAKBA vs ALLK Comparison
Open Charts AKBA vs ALLKBanner chart's image
Akebia Therapeutics
Price$1.84
Change-$0.00 (-0.00%)
Volume$23.9K
CapitalizationN/A
Allakos
Price$1.35
Change+$0.10 (+8.00%)
Volume$11.62K
CapitalizationN/A
View a ticker or compare two or three
AKBA vs ALLK Comparison Chart
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ALLK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
AKBA vs. ALLK commentary
Nov 06, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Buy and ALLK is a StrongBuy.

COMPARISON
Comparison
Nov 06, 2024
Stock price -- (AKBA: $1.85 vs. ALLK: $1.25)
Brand notoriety: AKBA and ALLK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 198% vs. ALLK: 84%
Market capitalization -- AKBA: $387.98M vs. ALLK: $111.06M
AKBA [@Biotechnology] is valued at $387.98M. ALLK’s [@Biotechnology] market capitalization is $111.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $498.83B to $0. The average market capitalization across the [@Biotechnology] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileALLK’s FA Score has 1 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • ALLK’s FA Score: 1 green, 4 red.
According to our system of comparison, ALLK is a better buy in the long-term than AKBA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 7 TA indicator(s) are bullish while ALLK’s TA Score has 5 bullish TA indicator(s).

  • AKBA’s TA Score: 7 bullish, 4 bearish.
  • ALLK’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, AKBA is a better buy in the short-term than ALLK.

Price Growth

AKBA (@Biotechnology) experienced а +13.19% price change this week, while ALLK (@Biotechnology) price change was -3.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +14.28%, and the average quarterly price growth was +9.90%.

Reported Earning Dates

AKBA is expected to report earnings on Mar 12, 2025.

ALLK is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($388M) has a higher market cap than ALLK($111M). AKBA YTD gains are higher at: 48.790 vs. ALLK (-54.212). AKBA has higher annual earnings (EBITDA): 4.63M vs. ALLK (-182.51M). ALLK has more cash in the bank: 123M vs. AKBA (39.5M). ALLK has less debt than AKBA: ALLK (39.7M) vs AKBA (49.5M). AKBA has higher revenues than ALLK: AKBA (174M) vs ALLK (0).
AKBAALLKAKBA / ALLK
Capitalization388M111M350%
EBITDA4.63M-182.51M-3%
Gain YTD48.790-54.212-90%
P/E RatioN/AN/A-
Revenue174M0-
Total Cash39.5M123M32%
Total Debt49.5M39.7M125%
FUNDAMENTALS RATINGS
AKBA vs ALLK: Fundamental Ratings
AKBA
ALLK
OUTLOOK RATING
1..100
1721
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
22
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3736
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALLK's Valuation (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for AKBA (72) in the Biotechnology industry. This means that ALLK’s stock grew somewhat faster than AKBA’s over the last 12 months.

ALLK's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that ALLK’s stock grew similarly to AKBA’s over the last 12 months.

ALLK's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that ALLK’s stock grew similarly to AKBA’s over the last 12 months.

ALLK's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as AKBA (37) in the Biotechnology industry. This means that ALLK’s stock grew similarly to AKBA’s over the last 12 months.

ALLK's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that ALLK’s stock grew similarly to AKBA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBAALLK
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 5 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
85%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ALLK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FBAK212.002.12
+1.01%
First National Bank Alaska
GLNCY10.49N/A
N/A
Glencore Plc
ANYYY21.78-0.56
-2.51%
Aena SME S.A.
CGLCF0.16N/A
-2.84%
Cassiar Gold Corp.
XISHY9.78-0.49
-4.80%
Xinyi Solar Holdings Limited

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with INZY. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+9.17%
INZY - AKBA
42%
Loosely correlated
+1.38%
BEAM - AKBA
41%
Loosely correlated
+6.24%
ABCL - AKBA
40%
Loosely correlated
+5.49%
CDXC - AKBA
37%
Loosely correlated
-1.79%
PRME - AKBA
36%
Loosely correlated
-1.49%
More

ALLK and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLK has been loosely correlated with AXON. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLK jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLK
1D Price
Change %
ALLK100%
-1.57%
AXON - ALLK
38%
Loosely correlated
+1.35%
PRME - ALLK
38%
Loosely correlated
-1.49%
ENSC - ALLK
36%
Loosely correlated
-12.60%
GNPX - ALLK
34%
Loosely correlated
-6.05%
AKBA - ALLK
34%
Loosely correlated
+9.17%
More